1: Menyhárt O, Győrffy B. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. Cancer Metastasis Rev. 2020 Mar;39(1):211-233. doi: 10.1007/s10555-020-09854-1. PMID: 31970590; PMCID: PMC7098941.
2: Fekete JT, Welker Á, Győrffy B. miRNA Expression Signatures of Therapy Response in Squamous Cell Carcinomas. Cancers (Basel). 2020 Dec 28;13(1):63. doi: 10.3390/cancers13010063. PMID: 33379285; PMCID: PMC7794682.
3: Wong CK, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Győrffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. Mol Cancer Res. 2020 Mar;18(3):414-423. doi: 10.1158/1541-7786.MCR-19-0525. Epub 2020 Jan 13. PMID: 31932471; PMCID: PMC7115128.
4: Awah CU, Chen L, Bansal M, Mahajan A, Winter J, Lad M, Warnke L, Gonzalez- Buendia E, Park C, Zhang D, Feldstein E, Yu D, Zannikou M, Balyasnikova IV, Martuscello R, Konerman S, Győrffy B, Burdett KB, Scholtens DM, Stupp R, Ahmed A, Hsu P, Sonabend AM. Ribosomal protein S11 influences glioma response to TOP2 poisons. Oncogene. 2020 Jul;39(27):5068-5081. doi: 10.1038/s41388-020-1342-0. Epub 2020 Jun 11. PMID: 32528131; PMCID: PMC7646677.
5: Zhu L, Hissa B, Győrffy B, Jann JC, Yang C, Reissfelder C, Schölch S. Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer. Diagnostics (Basel). 2020 May 15;10(5):305. doi: 10.3390/diagnostics10050305. PMID: 32429174; PMCID: PMC7278018.
6: El-Balat A, Karn T, Holtrich U, Becker S, Kommoss S, Győrffy B, Anglesio MS, Huntsman DG, Drosos Z, Rody A, Gevensleben H, Hanker LC. Histotype-specific
analysis of acid ceramidase expression in ovarian cancer. Virchows Arch. 2020 Jun;476(6):855-862. doi: 10.1007/s00428-019-02728-0. Epub 2020 Jan 2. PMID: 31897818.
7: Nagy Á, Pongor S, Győrffy B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. Int J Antimicrob Agents. 2021 Feb;57(2):106272. doi:
10.1016/j.ijantimicag.2020.106272. Epub 2020 Dec 23. PMID: 33347989; PMCID: PMC7755579.
8: Ai C, Zhang J, Lian S, Ma J, Győrffy B, Qian Z, Han Y, Feng Q. FOXM1 functions collaboratively with PLAU to promote gastric cancer progression. J Cancer. 2020 Jan 1;11(4):788-794. doi: 10.7150/jca.37323. PMID: 31949481; PMCID: PMC6959008.
9: Pálinkás HL, Békési A, Róna G, Pongor L, Papp G, Tihanyi G, Holub E, Póti Á, Gemma C, Ali S, Morten MJ, Rothenberg E, Pagano M, Szűts D, Győrffy B, Vértessy
BG. Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments. Elife. 2020 Sep 21;9:e60498. doi: 10.7554/eLife.60498. PMID: 32956035; PMCID: PMC7505663.
10: Zhu L, Kan KJ, Grün JL, Hissa B, Yang C, Győrffy B, Loges S, Reißfelder C, Schölch S. GAS2L1 Is a Potential Biomarker of Circulating Tumor Cells in Pancreatic Cancer. Cancers (Basel). 2020 Dec 15;12(12):3774. doi: 10.3390/cancers12123774. PMID: 33333841; PMCID: PMC7765300.
11: Periyasamy M, Singh AK, Gemma C, Farzan R, Allsopp RC, Shaw JA, Charmsaz S, Young LS, Cunnea P, Coombes RC, Győrffy B, Buluwela L, Ali S. Induction of
APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB. Oncogene. 2021 Feb;40(6):1077-1090. doi: 10.1038/s41388-020-01583-7. Epub 2020 Dec 15. PMID: 33323971; PMCID: PMC7116738.
12: Baster Z, Li L, Kukkurainen S, Chen J, Pentikäinen O, Győrffy B, Hytönen VP, Zhu H, Rajfur Z, Huang C. Cyanidin-3-glucoside binds to talin and modulates colon cancer cell adhesions and 3D growth. FASEB J. 2020 Feb;34(2):2227-2237. doi: 10.1096/fj.201900945R. Epub 2020 Jan 9. PMID: 31916632.
13: Augimeri G, La Camera G, Gelsomino L, Giordano C, Panza S, Sisci D, Morelli C, Győrffy B, Bonofiglio D, Andò S, Barone I, Catalano S. Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast Cancer Cells. Int J Mol Sci. 2020 Aug 14;21(16):5841. doi: 10.3390/ijms21165841. PMID: 32823947; PMCID: PMC7461508.
14: Shafran JS, Jafari N, Casey AN, Győrffy B, Denis GV. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):268-277. doi: 10.1038/s41391-020-0246-y. Epub 2020 Jul 21. PMID: 32690869; PMCID: PMC7855805.
15: Nagy Á, Győrffy B. muTarget: A platform linking gene expression changes and mutation status in solid tumors. Int J Cancer. 2021 Jan 15;148(2):502-511. doi: 10.1002/ijc.33283. Epub 2020 Sep 17. PMID: 32875562.
16: Fernandez AI, Geng X, Chaldekas K, Harris B, Duttargi A, Berry VL, Berry DL, Mahajan A, Cavalli LR, Győrffy B, Tan M, Riggins RB. The orphan nuclear receptor
estrogen-related receptor beta (ERRβ) in triple-negative breast cancer. Breast Cancer Res Treat. 2020 Feb;179(3):585-604. doi: 10.1007/s10549-019-05485-5. Epub 2019 Nov 19. PMID: 31741180; PMCID: PMC7153462.
17: Matsuyama T, Kandimalla R, Ishikawa T, Takahashi N, Yamada Y, Yasuno M, Kinugasa Y, Hansen TF, Fakih M, Uetake H, Győrffy B, Goel A. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. Int J Cancer. 2020 Dec 1;147(11):3250-3261. doi: 10.1002/ijc.33129. Epub 2020 Jul 13. PMID: 32657428; PMCID: PMC9192151.
18: Fan JB, Miyauchi S, Xu HZ, Liu D, Kim LJY, Burkart C, Cheng H, Arimoto KI, Yan M, Zhou Y, Győrffy B, Knobeloch KP, Rich JN, Cang H, Fu XD, Zhang DE. Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell- Mediated Tumor Killing. Cancer Discov. 2020 Mar;10(3):382-393. doi: 10.1158/2159-8290.CD-19-0608. Epub 2020 Jan 23. PMID: 31974171; PMCID: PMC7058499.
19: Pongor LS, Munkácsy G, Vereczkey I, Pete I, Győrffy B. Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting. Sci Rep. 2020 Sep 1;10(1):14403. doi: 10.1038/s41598-020-71382-3. PMID: 32873813; PMCID: PMC7463012.
20: Donini CF, El Helou M, Wierinckx A, Győrffy B, Aires S, Escande A, Croze S, Clezardin P, Lachuer J, Diab-Assaf M, Ghayad SE, Fervers B, Cavaillès V, Maguer- Satta V, Cohen PA. Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. Front Oncol. 2020 May 29;10:712. doi: 10.3389/fonc.2020.00712. PMID: 32670863; PMCID: PMC7326103.
21: Abdel-Fatah TMA, Ball GR, Thangavelu PU, Reid LE, McCart Reed AE, Saunus JM, Duijf PHG, Simpson PT, Lakhani SR, Pongor L, Gyorffy B, Moseley PM, Green AR, Pockley AG, Caldas C, Ellis IO, Chan SYT. Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer. JAMA Netw Open. 2020 Jul 1;3(7):e209486. doi: 10.1001/jamanetworkopen.2020.9486. PMID: 32633764; PMCID: PMC7341179.
22: Sawada Y, Kikugawa T, Iio H, Sakakibara I, Yoshida S, Ikedo A, Yanagihara Y, Saeki N, Győrffy B, Kishida T, Okubo Y, Nakamura Y, Miyagi Y, Saika T, Imai Y. GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer. Int J Cancer. 2020 Mar 1;146(5):1369-1382. doi: 10.1002/ijc.32554. Epub 2019 Jul 22. PMID: 31276604.
23: Fekete JT, Ősz Á, Pete I, Nagy GR, Vereczkey I, Győrffy B. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients. Gynecol Oncol. 2020 Mar;156(3):654-661. doi: 10.1016/j.ygyno.2020.01.006. Epub 2020 Jan 20. PMID: 31973910.
24: Serrano-Oviedo L, Nuncia-Cantarero M, Morcillo-Garcia S, Nieto-Jimenez C, Burgos M, Corrales-Sanchez V, Perez-Peña J, Győrffy B, Ocaña A, Galán-Moya EM. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer. Cell Oncol (Dordr). 2020 Jun;43(3):431-444. doi: 10.1007/s13402-020-00497-6. Epub 2020 Mar 12. PMID: 32166583; PMCID: PMC7214516.
25: Hargadon KM, Győrffy B, McGee TJ. Genomic and transcriptional changes in IFNγ pathway genes are putative biomarkers of response to ipilimumab immunotherapy in melanoma patients. Expert Rev Clin Immunol. 2020 Dec;16(12):1099-1103. doi: 10.1080/1744666X.2021.1847644. Epub 2020 Nov 15. PMID: 33151785.
26: Kim SJ, Ju JS, Kang MH, Eun JW, Kim YH, Raninga PV, Khanna KK, Győrffy B, Pack CG, Han HD, Lee HJ, Gong G, Shin Y, Mills GB, Eyun SI, Park YY. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020 Jul 2;10(18):7974-7992. doi: 10.7150/thno.45037. PMID: 32724453; PMCID: PMC7381744.
27: Cimas FJ, Manzano A, Baliu-Piqué M, García-Gil E, Pérez-Segura P, Nagy Á, Pandiella A, Győrffy B, Ocana A. Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. Cancers (Basel). 2020 Aug 11;12(8):2243. doi: 10.3390/cancers12082243. PMID: 32796628; PMCID: PMC7464853.
28: Hassan N, Rutsch N, Győrffy B, Espinoza-Sánchez NA, Götte M. SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells. Sci Rep. 2020 Feb 10;10(1):2262. doi: 10.1038/s41598-020-59057-5. PMID: 32042016; PMCID: PMC7010743.
29: Alcaraz-Sanabria A, Baliu-Piqué M, Saiz-Ladera C, Rojas K, Manzano A, Marquina G, Casado A, Cimas FJ, Pérez-Segura P, Pandiella A, Gyorffy B, Ocana A. Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. Front Oncol. 2020 Jan 10;9:1486. doi: 10.3389/fonc.2019.01486. PMID: 31998644; PMCID: PMC6965148.
30: Rödel F, Zhou S, Győrffy B, Raab M, Sanhaji M, Mandal R, Martin D, Becker S, Strebhardt K. The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression. Front Oncol. 2020 Oct 7;10:558932. doi: 10.3389/fonc.2020.558932. PMID: 33117692; PMCID: PMC7577119.